Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Slides:



Advertisements
Similar presentations
Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:
Advertisements

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
Randomized, double-blind, multicenter, controlled trial.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Proteinuria as a surrogate outcome in CKD UKPDS Rudy Bilous Middlesbrough, UK.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Renal damage occurs in 1 out of 4 hypertensives Adapted from Leoncini et al. J Hypertens. 2008;26:
Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
Trial profile Mann JF et al. Lancet 2008;372:
Serum Concentration of Cystatin C and Risk of End-Stage Renal Disease in Diabetes Featured Article: Andrzej S. Krolewski, M.D., Ph.D., James H. Warram,
The RAVE Study Renal Athersosclerotic Revascularization Evaluation Reference Tobe SW, Atri M, Perkins N, et al. Renal Athersosclerotic revascularization.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Section 4: Managing progression of CKD
The ALERT Trial.
Chronic Kidney Disease in Diabetes
Melody Sherwood, Peter A McCullough  The Lancet Global Health 
Primary end point of the ANZICS low-dose dopamine trial
Subclinical organ damage Treatment LVH
Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic
Nurses' Health Study: Risk of hypertension associated with >1000 µg/day of folate vs
Figure 4 Interplay between acute kidney injury (AKI),
Summary of Design Aim: Effect of Ramipril (up to 10mg/d) or Vit E (400 IU/d) vs its placebo on CV death, M I or stroke (primary) Design: Randomized double.
Adjusted mortality risk
Nat. Rev. Nephrol. doi: /nrneph
Creatinine clearance (mL/min) n All-cause mortality (%)
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
Nat. Rev. Nephrol. doi: /nrneph
Type 2 diabetes.
Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors
Relative risk of major events with atenolol vs placebo
Outcome Relative risk with beta blockers 95% CI Stroke –1.30
Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.
Melody Sherwood, Peter A McCullough  The Lancet Global Health 
Trial Selection Process
Your Kidneys May Outlive You
AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.
Nuhad Ismail, Bryan Becker, Piotr Strzelczyk, Eberhard Ritz 
The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study was a double-blind, randomized, placebo-controlled study.
Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:
Baseline Characteristics
Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:
Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation?  Pantelis A. Sarafidis, Luis.
Volume 67, Issue 1, Pages (January 2005)
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
The Lancet Diabetes & Endocrinology
Summary of trial identification and selection
Kotseva K, et al. Lancet 2009;373:929-40
Baseline characteristics of older women (NHS I), younger women (NHS II), and men (HPFS) with a history of hypertension according to thiazide use Eric N.
Prehypertension: is it relevant for nephrologists?
Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.
Standard mean difference of change in creatinine between the intravenous (IV) versus oral (PO) arm. Standard mean difference of change in creatinine between.
Attributed cause of end-stage renal disease (ESRD) among 251 patients with SLE in the Georgia Lupus Registry who progressed to ESRD (1979–2012), overall.
Low/moderate intensity statins High intensity statins
Presence of inpatient diagnostic codes for attributed cause of end-stage renal disease (ESRD) among 46 patients with systemic lupus erythematosus (SLE)
ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.
Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.
Correlations among chronic kidney disease (CKD) classification, urinary adiponectin level, eGFR, and ACR. (A) Correlation between CKD classification and.
Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.
Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.
Pathway to initial antihypertensive therapy in patients with diabetes
Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects.
Prevalence of nephropathy, retinopathy, and neuropathy in subjects achieving all (A) three targets, (B) two targets, (C) one target, and (D) none, and.
Predicted, unadjusted prevalence of aggregate MVD (retinopathy, nephropathy, and/or neuropathy) (A), nephropathy (B), retinopathy (C), and neuropathy (D)
Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.
Low/moderate intensity statins High intensity statins
Risk of mortality in patients with diabetes and ESRD
Presentation transcript:

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p Doubling of creatinine 0.71 (0.49-1.04) 0.07 End-stage renal disease 0.87 (0.75-0.99) 0.04 Casas JP et al. Lancet 2005; 366: 2026-2033

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs in diabetic nephropathy End point Relative risk (95% CI) Doubling of creatinine 1.09 (0.55-2.15) End-stage renal disease 0.89 (0.74-1.07) Casas JP et al. Lancet 2005; 366: 2026-2033

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.